The accumulation of MDSCs in the NASH liver of Ncoa5+/− mice can be prevented by long-term treatment of metformin, concurrent with a reduced HCC incidence [129]. The gene discussed is NCOA5; the disease is metabolic dysfunction-associated steatohepatitis.